The completed observational study titled 'Amyotrophic Lateral Sclerosis: a New Paradigm' focuses on the epidemiological and genetic characterization of ALS patients in a region of high prevalence in Portugal. Given the increasing incidence of ALS, particularly with bulbar involvement, there is a significant market opportunity for novel therapeutic interventions targeting genetic and environmental risk factors. The study's findings could inform future drug development and positioning within the ALS treatment landscape, which is currently limited by the lack of effective therapies. Companies focusing on genetic research and personalized medicine may find strategic partnerships or acquisition opportunities in this area. Additionally, the high prevalence of ALS in the studied region may attract interest from pharmaceutical companies looking to conduct further research or clinical trials.